Boehringer Ingelheim has announced a new diabetes collaboration with GWT and the department of medicine of the Technische Universitat (TU) Dresden.
The agreement will see the pharmaceutical company work alongside GWT, a company based at the German university, in order to conduct research into the causes of the disease.
Attentions will be focused on the link between excessive blood glucose and other complications of the condition, with the ultimate aim of translating these findings into the development of innovative new therapies.
Six individual research projects have initially been defined by the industry-academia collaboration, which will take advantage of the expertise of all partners.
Professor Wolfgang Rettig, senior vice-president of research at Boehringer Ingelheim, said: "This research partnership builds upon the excellent, shared experience gained from our earlier collaboration with the TU Dresden."
Last week, Boehringer Ingelheim announced the launch of Lean-to Clinic, a new programme that aims to deliver drug products for clients at an accelerated rate.